全球镰状细胞性贫血检测与筛检市场

预计到 2030 年全球镰状细胞性贫血检测和筛检市场规模将达到 7.154 亿美元

全球镰状细胞性贫血检测和筛检市场规模预计在2024年为4.13亿美元，到2030年将达到7.154亿美元，在2024-2030年的分析期内，复合年增长率为9.6%。血红素是本报告分析的细分市场之一，预计其复合年增长率为9.2%，到分析期结束时将达到3.383亿美元。高效液相层析细分市场在分析期间的复合年增长率预计为8.1%。

美国市场规模估计为 1.125 亿美元，中国市场预计复合年增长率为 13.0%

美国镰状性贫血检测和筛检市场规模预计在2024年达到1.125亿美元。作为世界第二大经济体，中国预计在2024年至2030年期间实现13.0%的复合年增长率，到2030年市场规模将达到1.448亿美元。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为6.9%和8.4%。在欧洲，预计德国的复合年增长率约为7.5%。

全球镰状细胞性贫血检测和筛检市场—主要趋势和驱动因素摘要

为什么镰状细胞性贫血检测成为全球医疗保健的优先事项？了解对早期诊断日益增长的需求

随着政府和医疗机构重视早期发现和疾病管理，镰状细胞性贫血的检测和筛检变得越来越重要。镰状细胞疾病 (SCD) 是一种遗传性血液疾病，影响全球数百万人，尤其是在非洲、中东、印度以及北美和南美部分地区等高发生率。早期诊断对于预防中风、器官损伤和剧烈疼痛等併发症至关重要。政府和医疗机构正在加强新生儿筛检项目，以确保早期疗育，从而改善患者预后并降低医疗成本。此外，婚前和产前筛检的扩大进一步要求需要可近且准确的检测解决方案。随着人们对镰状细胞疾病认识的提高，医疗保健系统正在整合先进的筛检技术，以促进早期发现和更好的治疗方案。

技术进步如何改善镰状细胞疾病检测？探索诊断准确性和可近性的创新

诊断技术的进步彻底改变了镰状细胞性贫血的检测，使得更准确、更快速、更经济的筛检方法成为可能。血红蛋白电泳和高效液相层析(HPLC) 等传统临床检测正在与新一代诊断工具相辅相成，例如照护现场(POC) 设备、自动分子检测和基因筛检技术。基于 CRISPR 的基因编辑研究也开闢了识别与镰状细胞疾病相关的基因突变的可能性，为精准医疗方法铺平了道路。此外，人工智慧诊断平台正在提高套件的准确性并减少假阳性和假阴性。分散式检查选项的扩展，例如家用和社区筛检套件，使得医疗基础设施有限的偏远地区更容易进行检测。随着检测技术的发展，镰状细胞性贫血的诊断正变得更有效率、经济实惠且在全球范围内可及。

阻碍镰状细胞侦测广泛应用的挑战有哪些？如何应对市场壁垒和医疗保健差异

儘管检测技术取得了进步，但镰状细胞性贫血筛检的广泛应用仍面临若干挑战。低收入地区有限的医疗基础设施阻碍了诊断工具的获取，从而限制了及时发现和治疗。分子和基因筛检方法的高成本造成了经济负担，并限制了服务不足人口获得优质医疗服务的机会。此外，人们对镰状细胞疾病和检测选择的认识有限，尤其是在开发中国家，导致诊断和介入的延迟。监管障碍和各地区检测指南不一致进一步使市场扩张复杂化，因此需要加强国际合作，以标准化筛检项目。应对这些挑战需要专注于医疗基础设施、政策改革和公共卫生宣传活动，以提高可及性和意识。

镰状细胞性贫血检测市场的成长动力是什么？关键扩张趋势和医疗保健倡议

镰状性贫血检测和筛检市场的成长受到多种因素的推动，包括政府资助的筛检计画、分子诊断技术的进步以及医疗资金的增加。国家强制要求的新生儿筛检在扩大早期检测工作方面发挥关键作用，刺激了对先进诊断技术的投资。发展中国家镰状细胞镰状盛行率的上升进一步推动了对经济实惠且可扩展的筛检解决方案的需求。此外，全球卫生组织和非营利组织正在资助研究和以地区为基础项目，以提高人们对疾病的认识并增加检测的可及性。基因检测服务的扩展和基于CRISPR的创新也促进了市场的成长，同时个人化医疗方法在镰状细胞性贫血管理中的广泛应用也促进了市场的成长。随着诊断技术的进步和全球改善疾病管理的努力不断加强，镰状性贫血检测市场预计将持续成长，并改善全球患者的治疗效果。

部分

技术（血红素、高效液相层析、就地检验、其他检测）；年龄层（1 岁以下、25-60 岁、其他）；产业类型（政府实验室、私人实验室、企业实验室、PPP）

受访公司范例

• Alpha Laboratories
• ASI（Analytical Services International）
• Atlas Medical
• Beam Therapeutics
• BioMedomics Inc.
• Bio-Rad Laboratories, Inc
• bluebird bio Inc.
• Bristol-Myers Squibb Company
• Cigna
• CRISPR Therapeutics
• Daktari Diagnostics
• Emmaus Life Sciences, Inc.
• Fisher Scientific
• Functional Fluidics
• Global Blood Therapeutics, Inc.（Pfizer Inc.）
• Hemex Health
• HEMEX HEALTH
• HemoTypeSC
• Imara Inc.
• KovaDx
• Laboratory Corporation of America Holdings
• LABS Inc.
• Mayo Clinic
• Modus Therapeutics
• Novartis AG
• Pfizer Inc.
• Quest Diagnostics
• Sanofi SA
• Silver Lake Research Corporation
• STRECK, INC

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地以及进出口情况（成品和原始OEM）预测其竞争地位的变化。这种复杂多变的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 比赛

Global Sickle Cell Anemia Testing and Screening Market to Reach US$715.4 Million by 2030

The global market for Sickle Cell Anemia Testing and Screening estimated at US$413.0 Million in the year 2024, is expected to reach US$715.4 Million by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Hemoglobin, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$338.3 Million by the end of the analysis period. Growth in the High-Performance Liquid Chromatography segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$112.5 Million While China is Forecast to Grow at 13.0% CAGR

The Sickle Cell Anemia Testing and Screening market in the U.S. is estimated at US$112.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$144.8 Million by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Sickle Cell Anemia Testing and Screening Market - Key Trends & Drivers Summarized

Why Is Sickle Cell Anemia Testing Becoming a Global Healthcare Priority? Understanding the Rising Demand for Early Diagnosis

Sickle cell anemia testing and screening have gained increasing importance as governments and healthcare institutions prioritize early detection and disease management. Sickle cell disease (SCD) is a genetic blood disorder that affects millions worldwide, particularly in regions with high prevalence rates, such as Africa, the Middle East, India, and parts of North and South America. Early diagnosis is crucial in preventing complications such as stroke, organ damage, and severe pain crises. Governments and health organizations have ramped up newborn screening programs to ensure early intervention, leading to improved patient outcomes and reduced healthcare costs. Additionally, the expansion of premarital and prenatal screening initiatives has further reinforced the need for accessible and accurate testing solutions. As awareness of sickle cell disease grows, healthcare systems are integrating advanced screening technologies to facilitate early identification and better treatment planning.

How Are Technological Advancements Improving Sickle Cell Testing? Exploring Innovations in Diagnostic Accuracy and Accessibility

Advancements in diagnostic technology have revolutionized sickle cell anemia testing, enabling more precise, rapid, and cost-effective screening methods. Traditional laboratory tests, such as hemoglobin electrophoresis and high-performance liquid chromatography (HPLC), have been complemented by next-generation diagnostic tools, including point-of-care (POC) testing devices, automated molecular assays, and genetic screening techniques. CRISPR-based gene-editing research has also opened possibilities for identifying genetic mutations associated with sickle cell disease, paving the way for precision medicine approaches. Furthermore, AI-powered diagnostic platforms are enhancing interpretation accuracy, reducing false positives and negatives. The expansion of decentralized testing options, including at-home and community-based screening kits, has made testing more accessible in remote areas with limited healthcare infrastructure. As testing technology continues to evolve, sickle cell anemia diagnostics are becoming more efficient, affordable, and globally accessible.

What Challenges Are Hindering the Adoption of Sickle Cell Testing? Addressing Market Barriers and Healthcare Disparities

Despite the advancements in testing technology, several challenges limit the widespread adoption of sickle cell anemia screening. Limited healthcare infrastructure in low-income regions has hindered the availability of diagnostic tools, restricting access to timely detection and treatment. The high costs associated with molecular and genetic screening methods also pose affordability concerns, making it difficult for underprivileged populations to access quality care. Additionally, inadequate awareness about sickle cell disease and testing options has led to underdiagnosis and delayed interventions, particularly in developing nations. Regulatory hurdles and inconsistent testing guidelines across different regions further complicate market expansion, requiring greater international collaboration to standardize screening programs. Addressing these challenges will require targeted investments in healthcare infrastructure, policy reforms, and public health campaigns to increase accessibility and awareness.

What’s Driving the Growth of the Sickle Cell Anemia Testing Market? Identifying Key Expansion Trends and Healthcare Initiatives

The growth in the sickle cell anemia testing and screening market is driven by several factors, including government-backed screening programs, advancements in molecular diagnostics, and increased healthcare funding. National newborn screening mandates have played a crucial role in expanding early detection efforts, prompting investments in advanced diagnostic technologies. The rising prevalence of sickle cell disease in developing countries has further accelerated the demand for affordable and scalable screening solutions. Additionally, global health organizations and non-profit initiatives are funding research and community-based programs to enhance disease awareness and testing accessibility. The expansion of genetic testing services and CRISPR-based innovations has also contributed to market growth, as personalized medicine approaches gain traction in managing sickle cell disease. With ongoing advancements in diagnostics and increasing global efforts to improve disease management, the market for sickle cell anemia testing is expected to witness sustained growth, improving patient outcomes worldwide.

SCOPE OF STUDY:

The report analyzes the Sickle Cell Anemia Testing and Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests, Other Tests); Age Group (Below 1 yr, 25 - 60 yrs, Others); Sector Type (Government Labs, Private Labs, Corporate Labs, PPP)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Alpha Laboratories
• ASI (Analytical Services International)
• Atlas Medical
• Beam Therapeutics
• BioMedomics Inc.
• Bio-Rad Laboratories, Inc
• bluebird bio Inc.
• Bristol-Myers Squibb Company
• Cigna
• CRISPR Therapeutics
• Daktari Diagnostics
• Emmaus Life Sciences, Inc.
• Fisher Scientific
• Functional Fluidics
• Global Blood Therapeutics, Inc. (Pfizer Inc.)
• Hemex Health
• HEMEX HEALTH
• HemoTypeSC
• Imara Inc.
• KovaDx
• Laboratory Corporation of America Holdings
• LABS Inc.
• Mayo Clinic
• Modus Therapeutics
• Novartis AG
• Pfizer Inc.
• Quest Diagnostics
• Sanofi SA
• Silver Lake Research Corporation
• STRECK, INC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Sickle Cell Anemia Testing and Screening - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Awareness of Hereditary Blood Disorders Throws the Spotlight on Sickle Cell Screening Programs
  • Expansion of Neonatal and Prenatal Genetic Screening Drives Early Diagnosis of Sickle Cell Anemia
  • OEM Innovation in Point-of-Care Diagnostic Devices Enhances Access in Low-Infrastructure Settings
  • Growth in National Health Missions and Public Health Campaigns Spurs Universal Screening Mandates
  • OEM Development of Cost-Effective, High-Accuracy Lateral Flow Assays Supports Rural Deployment
  • Rising Birth Prevalence in Sub-Saharan Africa, India, and Middle East Expands Addressable Market
  • OEM Integration of Multiplex Testing Platforms Improves Detection Accuracy and Workflow Efficiency
  • Regulatory Support for Newborn Screening and Carrier Testing Strengthens Diagnostic Uptake
  • Surge in Gene Therapy Clinical Trials Promotes Pre-Treatment Genotyping and Risk Stratification
  • OEM Collaboration With Blood Banks and Pediatric Hospitals Enhances Institutional Testing Infrastructure
  • Expansion of Community-Based Outreach Models Encourages Voluntary Screening and Genetic Counseling
  • OEM Focus on Mobile Diagnostic Vans and Home Collection Models Expands Reach in Underserved Regions
  • Increasing Use of Telemedicine for Genetic Interpretation and Counseling Supports Screening Continuity
  • OEM Investment in Digital Records and National Screening Registries Enhances Patient Tracking
  • Rising Support From NGOs and Global Health Agencies Drives Free or Subsidized Testing Programs
  • OEM Partnerships With Pharma Companies Enable Companion Diagnostics in Targeted SCD Treatments
  • Growth in Workplace and School-Based Screening Initiatives Supports Preventive Health Policies
  • OEM Innovation in Saliva and Dried Blood Spot Sampling Improves Testing in Infants and Adolescents
  • Shift Toward Carrier Identification and Premarital Screening Programs Promotes Informed Reproductive Choices
  • Focus on Equity, Inclusion, and Stigma Reduction Enhances Public Acceptance of Mass Screening Campaigns
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Sickle Cell Anemia Testing and Screening Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Hemoglobin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Hemoglobin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Hemoglobin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for High-Performance Liquid Chromatography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for High-Performance Liquid Chromatography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for High-Performance Liquid Chromatography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Point-of-Care Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Point-of-Care Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Point-of-Care Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Corporate Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Corporate Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Corporate Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for PPP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for PPP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for PPP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Government Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Government Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Government Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Private Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Private Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Private Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Below 1 yr by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Below 1 yr by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Below 1 yr by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for 25 - 60 yrs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for 25 - 60 yrs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for 25 - 60 yrs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• JAPAN
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• CHINA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• EUROPE
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• FRANCE
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• GERMANY
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• INDIA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
• AFRICA
  • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030

IV. COMPETITION